| 000 | 01908 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517155817.0 | ||
| 264 | 0 | _c20191231 | |
| 008 | 201912s 0 0 eng d | ||
| 022 | _a1029-2403 | ||
| 024 | 7 |
_a10.1080/10428194.2017.1321750 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRobak, Tadeusz | |
| 245 | 0 | 0 |
_aAssociation between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _c01 2019 |
||
| 300 |
_a172-179 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aBortezomib _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Mantle-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProgression-Free Survival |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aHuang, Huiqiang | |
| 700 | 1 | _aJin, Jie | |
| 700 | 1 | _aZhu, Jun | |
| 700 | 1 | _aLiu, Ting | |
| 700 | 1 | _aSamoilova, Olga | |
| 700 | 1 | _aPylypenko, Halyna | |
| 700 | 1 | _aVerhoef, Gregor | |
| 700 | 1 | _aSiritanaratkul, Noppadol | |
| 700 | 1 | _aOsmanov, Evgenii | |
| 700 | 1 | _aPereira, Juliana | |
| 700 | 1 | _aMayer, Jiri | |
| 700 | 1 | _aHong, Xiaonan | |
| 700 | 1 | _aOkamoto, Rumiko | |
| 700 | 1 | _aPei, Lixia | |
| 700 | 1 | _aRooney, Brendan | |
| 700 | 1 | _avan de Velde, Helgi | |
| 700 | 1 | _aCavalli, Franco | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 60 _gno. 1 _gp. 172-179 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/10428194.2017.1321750 _zAvailable from publisher's website |
| 999 |
_c27247523 _d27247523 |
||